Open Access

Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non‑obese type 2 diabetic Goto‑Kakizaki rats

  • Authors:
    • Jantira Sanit
    • Eakkapote Prompunt
    • Punyanuch Adulyaritthikul
    • Nuttikarn Nokkaew
    • Podsawee Mongkolpathumrat
    • Kantapich Kongpol
    • Anusak Kijtawornrat
    • Soontaree Petchdee
    • Stephanie Barrère‑Lemaire
    • Sarawut Kumphune
  • View Affiliations

  • Published online on: July 10, 2019     https://doi.org/10.3892/etm.2019.7763
  • Pages: 1701-1714
  • Copyright: © Sanit et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Diabetic cardiomyopathy, especially myocardial ischemia reperfusion (I/R) injury, is a major cause of morbidity and mortality in type 2 diabetic patients. The increasing of basal p38 MAP Kinase (p38 MAPK) activation is a major factor that aggravates cardiac death on diabetic cardiomyopathy. In addition, metformin also shows cardio‑protective effects on myocardial ischemia/reperfusion injury. In this study, we investigated the effect of the combination between metformin and p38 MAPK inhibitor (SB203580) in diabetic rats subjected to I/R injury. H9c2 cells were induced into a hyperglycemic condition and treated with metformin, SB203580 or the combination of metformin and SB203580. In addition, cells in both the presence and absence of drug treatment were subjected to simulated ischemia/reperfusion injury. Cell viability and cellular reactive oxygen species (ROS) were determined. Moreover, the Goto‑Kakizaki (GK) rats were treated with metformin, SB203580, and the combination of metformin and SB203580 for 4 weeks. Diabetic parameters and cardiac functions were assessed. Finally, rat hearts were induced ischemia/reperfusion injury for the purpose of infarct size analysis and determination of signal transduction. A high‑glucose condition did not reduce cell viability but significantly increased ROS production and significantly decreased cell viability after induced sI/R. Treatment using drugs was shown to reduce ROS generation and cardiac cell death. The GK rats displayed diabetic phenotype by increasing diabetic parameters and these parameters were significantly decreased when treated with drugs. Treatment with metformin or SB203580 could significantly reduce the infarct size. Interestingly, the combination of metformin and SB203580 could enhance cardio‑protective ability. Myocardial I/R injury significantly increased p38 MAPK phosphorylation, Bax/Bcl‑2 ratio and caspase‑3 level. Treatment with drugs significantly decreased the p38 MAPK phosphorylation, Bax/Bcl‑2 ratio, caspase‑3 level and increased Akt phosphorylation. In conclusion, using the combination of metformin and SB203580 shows positive cardio‑protective effects on diabetic ischemic cardiomyopathy.

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sanit, J., Prompunt, E., Adulyaritthikul, P., Nokkaew, N., Mongkolpathumrat, P., Kongpol, K. ... Kumphune, S. (2019). Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non‑obese type 2 diabetic Goto‑Kakizaki rats. Experimental and Therapeutic Medicine, 18, 1701-1714. https://doi.org/10.3892/etm.2019.7763
MLA
Sanit, J., Prompunt, E., Adulyaritthikul, P., Nokkaew, N., Mongkolpathumrat, P., Kongpol, K., Kijtawornrat, A., Petchdee, S., Barrère‑Lemaire, S., Kumphune, S."Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non‑obese type 2 diabetic Goto‑Kakizaki rats". Experimental and Therapeutic Medicine 18.3 (2019): 1701-1714.
Chicago
Sanit, J., Prompunt, E., Adulyaritthikul, P., Nokkaew, N., Mongkolpathumrat, P., Kongpol, K., Kijtawornrat, A., Petchdee, S., Barrère‑Lemaire, S., Kumphune, S."Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non‑obese type 2 diabetic Goto‑Kakizaki rats". Experimental and Therapeutic Medicine 18, no. 3 (2019): 1701-1714. https://doi.org/10.3892/etm.2019.7763